A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer

• Status: Completed
• Trial end date: 2009-11-24

Summary

This study will characterize the effect of elevated gastric pH mediated by the proton-pump inhibitor, esomeprazole, on the relative bioavailability of lapatinib in subjects with metastatic ErbB2 positive breast cancer.

• Phase: Phase 1

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Esomeprazole; Lapatinib